AbbVie Inc. (NEO:ABBV)

Canada flag Canada · Delayed Price · Currency is CAD
32.51
-0.21 (-0.64%)
Oct 14, 2025, 3:50 PM EDT
-0.64%
Market Cap568.61B
Revenue (ttm)79.55B
Net Income (ttm)5.08B
Shares Outn/a
EPS (ttm)2.86
PE Ratio111.98
Forward PE19.60
Dividendn/a
Ex-Dividend Daten/a
Volume2,722
Average Volume4,747
Open32.50
Previous Close32.72
Day's Range32.46 - 32.59
52-Week Range23.68 - 34.48
Beta0.51
RSI58.33
Earnings DateOct 29, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Sector Healthcare
Founded 2012
Employees 55,000
Stock Exchange Cboe Canada
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements

News

There is no news available yet.